Last updated: August 2, 2026
ecutive summary: Technescan MAG3 is a mature, single-source nuclear medicine diagnostic kit containing mertiatide for preparation of technetium Tc-99m mertiatide injection. Its commercial value comes from recurring renal-imaging demand, clinical preference in patients with reduced renal function, and radiopharmacy infrastructure rather than patent exclusivity. Public sources do not disclose product-level revenue, profit, or unit-volume data. The principal commercial risks are radiopharmaceutical supply interruptions, hospital budget pressure, reimbursement changes, and substitution by technetium Tc-99m DTPA, ultrasound, CT, or MR-based testing.
Technescan MAG3 Market Dynamics, Financial Trajectory, Patents, and Competitive Position
What is Technescan MAG3 and how is it used?
Technescan MAG3 is a prescription diagnostic kit used to prepare technetium Tc-99m mertiatide injection for renal imaging. Mertiatide is also known as mercaptoacetyltriglycine, MAG3, or betiatide.
The product is used for:
- Renal perfusion and function imaging
- Differential renal function assessment
- Evaluation of urinary tract obstruction
- Assessment of renal drainage
- Pediatric renal imaging
- Renal studies in patients with impaired kidney function
The kit does not contain radioactive technetium at the time of manufacture. A nuclear pharmacy or authorized radiopharmacy adds technetium Tc-99m sodium pertechnetate before administration. The finished radiopharmaceutical has a short effective commercial life because Tc-99m has a physical half-life of about six hours.
The FDA-approved product is associated with NDA 020059 and has an initial U.S. approval dating to the mature nuclear medicine market era. Current U.S. labeling identifies Curium US LLC as the marketing company for the product.[1]
How does MAG3 work in renal imaging?
Tc-99m mertiatide is cleared primarily through tubular secretion. Compared with Tc-99m DTPA, MAG3 generally provides stronger renal extraction and better image quality when glomerular filtration is reduced. That characteristic supports continued use in patients with compromised renal function, neonates, infants, and patients with suspected obstruction.[1,2]
Typical adult administration is within the range of 37 to 185 MBq, or 1 to 5 mCi, depending on the imaging protocol and clinical indication. Pediatric dosing is weight-based and follows nuclear medicine protocols.[1]
What is the FDA regulatory status of Technescan MAG3?
Technescan MAG3 is an FDA-approved prescription diagnostic drug marketed under a New Drug Application. It is not a biologic, vaccine, cell therapy, or therapeutic small molecule.
| Regulatory item |
Status |
| Active ingredient |
Mertiatide, also called MAG3 or betiatide |
| Diagnostic radionuclide |
Technetium Tc-99m |
| Dosage form |
Kit for preparation of an injectable radiopharmaceutical |
| FDA pathway |
NDA |
| U.S. NDA |
020059 |
| Therapeutic category |
Renal diagnostic imaging agent |
| Product type |
Prescription radiopharmaceutical kit |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Possible through an ANDA or other applicable abbreviated pathway, subject to FDA requirements |
| Initial U.S. approval |
1990, according to product labeling |
| Current U.S. marketer |
Curium US LLC, according to current labeling |
The product is not protected by the biologic exclusivity framework. It also does not receive the market exclusivity profile associated with a recently approved innovative drug.
What patents protect Technescan MAG3?
Public FDA product information does not identify an active Orange Book patent barrier for Technescan MAG3. The product is a mature diagnostic kit, and its commercial position depends more on manufacturing capability, radiopharmacy relationships, regulatory compliance, and technetium supply than on enforceable composition-of-matter exclusivity.
| IP category |
Commercial assessment |
| Composition-of-matter patent |
No active Orange Book barrier identified in the cited FDA materials |
| Formulation patent |
No active Orange Book barrier identified |
| Method-of-use patent |
No active Orange Book barrier identified |
| Device or delivery patent |
Not material to the marketed kit |
| Manufacturing know-how |
Potentially important, but generally not visible in the Orange Book |
| Trade secrets |
Possible in precursor synthesis, kit manufacture, quality control, and radiolabeling procedures |
| Patent litigation exposure |
Low relative to recently launched specialty drugs |
| Regulatory switching cost |
Moderate because radiopharmacy manufacturing and validated kit production are required |
Patent expiry is therefore not the main determinant of generic entry. A competitor would still need an FDA-approved product, compliant manufacturing, suitable precursor chemistry, reliable quality controls, and distribution into radiopharmacies.
What is the Orange Book status of Technescan MAG3?
The FDA Orange Book is the principal U.S. reference for approved drug products, therapeutic equivalence codes, patent listings, and regulatory exclusivities.[3] Technescan MAG3 is a mature NDA product, but the cited public materials do not indicate an active patent or regulatory exclusivity period that would block an abbreviated competitor.
The practical implication is important: a new entrant would not need to wait for a clearly defined branded patent expiry date. Entry timing would depend on FDA approval, product development, manufacturing readiness, and commercial access.
The absence of a listed patent does not eliminate all legal risk. A competitor could face:
- Manufacturing-process disputes
- Trade-secret claims
- Contractual disputes with suppliers or radiopharmacy networks
- Regulatory disputes concerning equivalence or labeling
- State-law commercial claims
- Patent claims outside the Orange Book
No product-specific settlement agreement or Paragraph IV settlement is identified in the cited FDA materials.
When does Technescan MAG3 lose exclusivity?
Technescan MAG3 has already passed the period of conventional new-drug market exclusivity. The commercial product is in a post-exclusivity phase.
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not identified |
| Pediatric exclusivity |
Not identified as a current barrier |
| Qualified infectious-disease exclusivity |
Not applicable |
| Biologic exclusivity |
Not applicable |
| Listed patent exclusivity |
No active barrier identified in the cited materials |
This does not mean that multiple interchangeable products are guaranteed to launch. Radiopharmaceutical markets can remain concentrated even after exclusivity ends because demand is specialized, production is regulated, and products require time-sensitive logistics.
How large is the Technescan MAG3 market?
No public source cited here reports standalone Technescan MAG3 revenue, gross margin, prescriptions, or annual unit volume. Curium is a private nuclear medicine company, and hospitals generally report renal imaging through procedure and facility claims rather than by individual radiopharmaceutical brand.
The relevant market is the renal nuclear imaging segment, not the total pharmaceutical market. Demand is influenced by:
- The number of renal scans performed.
- The share of scans using MAG3 rather than DTPA or non-nuclear imaging.
- Radiopharmacy purchasing patterns.
- Hospital and outpatient imaging reimbursement.
- Availability of Tc-99m generators and distribution capacity.
- Use in pediatric and low-function kidneys, where MAG3 has a clinical advantage.
MAG3 is likely a small product by pharmaceutical revenue but an important product within renal nuclear medicine. Its value is recurring and operational rather than driven by premium specialty-drug pricing.
What is the financial trajectory for Technescan MAG3?
The likely financial profile is mature, stable, and supply-chain sensitive.
| Financial driver |
Effect on product trajectory |
| Patent expiry |
Limited incremental impact because the product is already post-exclusivity |
| Volume |
Linked to renal imaging procedures and nuclear medicine utilization |
| Price |
Constrained by hospital purchasing and radiopharmacy contracting |
| Gross margin |
Influenced by kit manufacturing, quality systems, distribution, and wastage |
| Revenue visibility |
Low because product-level sales are not publicly reported |
| Growth potential |
Moderate only if renal imaging volumes, market share, or geographic distribution expand |
| Downside risk |
Supply interruption, substitution, reimbursement pressure, or competitor entry |
| Cash-flow profile |
Potentially resilient because demand is recurring and clinical use is established |
The short shelf life of Tc-99m creates an unusual economics profile. Inventory cannot be managed like a conventional oral solid. Radiopharmacies coordinate production, delivery, and patient scheduling around isotope availability. A product shortage can create immediate procedure delays, while excess prepared doses can produce waste.
The commercial owner can preserve value through manufacturing reliability, broad radiopharmacy distribution, validated kit performance, and regulatory execution. Price increases are more difficult to sustain when hospitals can shift to DTPA or other diagnostic approaches.
What formulations are protected by Technescan MAG3?
Technescan MAG3 is marketed as a kit rather than as a ready-to-use radioactive injection. The kit contains nonradioactive components that are combined with Tc-99m sodium pertechnetate before use.
The formulation and manufacturing barriers include:
- Control of the mertiatide precursor
- Stannous reduction chemistry
- Radiochemical purity
- Sterility and endotoxin control
- Stability before and after radiolabeling
- Compatibility with radiopharmacy procedures
- Reliable labeling yield
- Dose calibration and quality testing
These operational requirements can deter entry even without patent protection. A technically equivalent product must perform consistently across radiopharmacy settings and meet FDA standards for a radiopharmaceutical kit.
Which companies compete with Technescan MAG3?
The competitive landscape has two levels: direct radiopharmaceutical competition and clinical substitution.
Direct and near-direct competitors
The principal alternative renal radiopharmaceutical is technetium Tc-99m diethylenetriaminepentaacetic acid, or Tc-99m DTPA. DTPA is used for renal perfusion and filtration studies, but MAG3 is often favored when renal function is reduced because of its stronger tubular extraction.
Other nuclear medicine agents may be used for specific renal questions, including Tc-99m dimercaptosuccinic acid, or DMSA, for cortical imaging and scarring. These products are not full substitutes for MAG3 in every protocol.
Non-nuclear imaging substitutes
Ultrasound, CT urography, MR urography, and laboratory-based renal assessment can replace some renal nuclear medicine studies. Substitution depends on the clinical question:
- Ultrasound is widely used for hydronephrosis and structural assessment.
- CT provides anatomic detail but carries radiation exposure and may require iodinated contrast.
- MR urography can provide an alternative in selected patients.
- Nuclear imaging remains valuable for functional drainage and differential renal function.
Technescan MAG3 therefore competes against diagnostic pathways, not only against branded radiopharmaceuticals.
What generic entry risks exist for Technescan MAG3?
Generic or alternative-product risk is structurally credible but commercially uneven.
A competitor could pursue an abbreviated regulatory route if it can demonstrate the required pharmaceutical equivalence, quality, labeling, and performance. The main barriers would be:
- Specialized sterile manufacturing
- Controlled access to precursor materials
- Radiochemical validation
- FDA inspection readiness
- Distribution to radiopharmacies
- Tc-99m supply coordination
- Hospital formulary and protocol adoption
- Sufficient market scale to justify manufacturing investment
A successful entrant could pressure price and increase hospital purchasing leverage. The incumbent would retain advantages from established clinical protocols, radiopharmacy familiarity, supply reliability, and existing contracts.
What manufacturing and supply-chain risks affect Technescan MAG3?
The product depends on two linked supply chains:
- Manufacture and distribution of the MAG3 kit.
- Availability of Tc-99m generated from molybdenum-99.
Tc-99m availability is affected by reactor outages, molybdenum production, generator logistics, transportation, and radiopharmacy scheduling. FDA shortage information and nuclear medicine industry guidance show that radiopharmaceutical supply risk can affect patient procedures even when the finished kit itself is available.[4,5]
For Technescan MAG3, supply resilience is a commercial asset. A competitor with a lower price but unreliable delivery may not displace the incumbent in hospitals that prioritize scheduled imaging capacity.
What patent litigation affects Technescan MAG3?
No active patent litigation, Paragraph IV challenge, or settlement agreement affecting Technescan MAG3 is identified in the cited public FDA materials. The product's principal legal risks are more likely to arise from regulatory compliance, manufacturing quality, supply contracts, and commercial distribution than from Orange Book patent enforcement.
Because the product is a diagnostic radiopharmaceutical kit, litigation economics differ from those for high-revenue oncology or immunology products. The smaller addressable market limits the expected value of expensive patent litigation.
How does Technescan MAG3 compare with Tc-99m DTPA?
| Attribute |
Technescan MAG3 |
Tc-99m DTPA |
| Primary renal handling |
Tubular secretion |
Glomerular filtration |
| Use in reduced renal function |
Often preferred |
May provide weaker extraction and lower image quality |
| Functional drainage assessment |
Strong clinical role |
Used, but less favored in some impaired-function settings |
| Pediatric use |
Established |
Used depending on protocol |
| Commercial positioning |
Specialty renal diagnostic kit |
Broader renal nuclear imaging alternative |
| Key substitution risk |
DTPA and non-nuclear imaging |
MAG3 in patients requiring stronger extraction |
MAG3's clinical differentiation is strongest in functional renal imaging when extraction and drainage information are important. DTPA remains a credible alternative, particularly where protocol, availability, or local practice favors it.
Is there biosimilar risk for Technescan MAG3?
Biosimilar risk is not applicable. Technescan MAG3 is not a biologic. The relevant threat is an abbreviated generic or competing radiopharmaceutical kit, along with clinical substitution by other imaging modalities.
What is the geographic coverage of Technescan MAG3?
The product's commercial value is strongest in markets with:
- Established nuclear medicine departments
- Reliable Tc-99m generator access
- Radiopharmacy distribution
- Reimbursement for functional renal imaging
- Pediatric and urologic imaging demand
U.S. performance is tied to FDA approval and domestic radiopharmacy infrastructure. International availability depends on country-specific registrations, isotope supply, local manufacturing, and reimbursement. Product-level geographic revenue is not publicly disclosed.
Key takeaways
- Technescan MAG3 is a mature FDA-approved renal diagnostic radiopharmaceutical kit containing mertiatide.
- The product has no meaningful remaining new-drug exclusivity.
- No active Orange Book patent barrier is identified in the cited FDA materials.
- Product-level revenue and profitability are not publicly disclosed.
- Commercial value depends on renal imaging volume, clinical preference, radiopharmacy access, and supply reliability.
- MAG3 has a clinical advantage over Tc-99m DTPA in many patients with reduced renal function.
- Generic entry is technically possible but constrained by sterile manufacturing, radiochemical quality, distribution, and limited market scale.
- Biosimilar risk does not apply.
- The main financial risks are isotope disruption, hospital price pressure, imaging substitution, and competitor supply reliability.
- The product is more strategically important as a dependable nuclear medicine platform product than as a high-growth pharmaceutical asset.
FAQs
Does Technescan MAG3 have a patent expiration date?
No active Orange Book patent expiry date is identified in the cited FDA materials. Its commercial exclusivity is already mature and post-patent in practical terms.
Is Technescan MAG3 a generic drug?
It is a branded FDA-approved diagnostic kit. A competing mertiatide kit could potentially enter through an abbreviated regulatory pathway, but product availability depends on FDA approval and specialized radiopharmaceutical manufacturing.
Who manufactures Technescan MAG3?
Current U.S. labeling identifies Curium US LLC as the marketing company. The product is distributed through the nuclear medicine and radiopharmacy supply chain.[1]
Can Tc-99m DTPA replace Technescan MAG3?
DTPA can replace MAG3 in some renal imaging protocols, but it is not a complete clinical substitute. MAG3 is often favored when renal function is impaired or when tubular extraction and drainage assessment are important.
Is Technescan MAG3 affected by technetium-99m shortages?
Yes. The MAG3 kit requires Tc-99m sodium pertechnetate for preparation. Disruptions in molybdenum-99 production, Tc-99m generator availability, transportation, or radiopharmacy operations can affect product use.
References
-
Curium US LLC. (n.d.). Technescan MAG3: Kit for the preparation of technetium Tc 99m mertiatide injection, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
Taylor, A. T., Blaufox, M. D., Seigel, B. A., et al. (2018). SNMMI procedure standard/EANM practice guideline for renal scintigraphy in adults. Journal of Nuclear Medicine Technology, 46(1), 4-13. https://doi.org/10.2967/jnmt.117.197442
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
-
International Atomic Energy Agency. (n.d.). Molybdenum-99 and technetium-99m supply. https://www.iaea.org/activities/technetium-99m-supply-chain and
